Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Charles C. Dorego | M | - |
Cynvec LLC
 Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | - |
| Richard Purcell | M | 63 |
Cynvec LLC
Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | - |
| Steve Blumenthal | M | - |
Cynvec LLC
Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | - |
| Robert Ivanhoe | M | - |
Cynvec LLC
Cynvec LLC Pharmaceuticals: MajorHealth Technology Cynvec LLC develops oncolytic therapeutics for the treatment of cancer. It offers cancer treatment platform to activate the body’s own immune system to safely attack tumors and prevent or slow cancer recurrence. The firm develops CYN-101, a bioengineered Sindbis viral vector vaccine expressing the NY-ESO-1 tumor associated antigen for the treatment of late-stage ovarian cancer; and an immunotherapeutic vaccine for multiple possible cancer targets. The company was founded in 2004 and is headquartered in New York, NY. | 18 years |
Connections Chart
Multi-company connection
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 4 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Leonard Litwin
- Personal Network
